Johnson & Johnson Lung Cancer Drug Gets Health Canada Approval
By Michael Susin
Johnson & Johnson said the Canadian health authority issued a notice of compliance for its lung-cancer treatment, meaning the drug is authorized to be marketed under certain conditions.
The pharmaceutical group said Health Canada approved the use of its asset Rybrevant, in combination with chemotherapy, for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer with activating epidermal growth factor receptor Exon 20 insertion mutations.
The notice of compliance is based on results from a late-stage study, which demonstrated a clinically meaningful and statistically significant improvement in progression-free survival and a 60% reduction in the risk of disease progression or death compared to chemotherapy alone.
"This approval reinforces our commitment to developing novel therapies, particularly for underserved patient populations with significant unmet needs," Janssen Inc.'s President Berkeley Vincent said. Janssen Inc. is a Johnson & Johnson company.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
July 03, 2024 08:43 ET (12:43 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Markets Brief: Q2 Earnings Season Begins With the Banks
-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
SolarEdge Stock Is Down 74% In 2024. Is It a Buy or a Sell?
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services